The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Open accessAbstract
T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have shown remarkable success in treating patients with hematologic malignancies and revitalized the field of adoptive cell therapy. However, realizing broader therapeutic applications of CAR-T cells necessitates engineering approaches on multiple levels to enhance efficacy and safety. Particularly, solid tumors present unique challenges due to the biological complexity of the solid-tumor microenvironment (TME). In this review, we highlight recent strategies to improve CAR-T cell therapy by engineering (1) the CAR protein, (2) T cells, and (3) the interaction between T cells and other components in the TME.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,342
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., & Alber, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.747 · Cited by 1,983
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Induction of T Cell Development from Hematopoietic Progenitor Cells by Delta-like-1 In Vitro
Schmitt, T. M., & Zúñiga-Pflücker, J. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00474-0 · Cited by 1,120
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,074
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Yang, W., Bai, Y., Xiong, Y., Zhang, J., Chen, S., Zheng, X., Meng, X., Li, L., Wang, J., Xu, C., et al. (2016) · Nature · doi:10.1038/nature17412 · Cited by 1,010
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,000
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Wang, D. (2006) · Gut · doi:10.1136/gut.2004.047100 · Cited by 899
Therapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. (2017) · Nature · doi:10.1038/nature22395 · Cited by 879
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M. M., Marchetti, D., & Dotti, G. (2015) · Nature Medicine · doi:10.1038/nm.3833 · Cited by 814
Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 792
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
An inducible caspase 9 safety switch for T-cell therapy
Straathof, K. C., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 742
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 706
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Cho, J. H., Collins, J. J., & Wong, W. W. (2018) · Cell · doi:10.1016/j.cell.2018.03.038 · Cited by 682
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Ionic immune suppression within the tumour microenvironment limits T cell effector function
Eil, R., Vodnala, S. K., Clever, D., Klebanoff, C. A., Sukumar, M., Pan, J. H., Palmer, D. C., Gros, A., Yamamoto, T. N., Patel, S. J., et al. (2016) · Nature · doi:10.1038/nature19364 · Cited by 678
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
Wang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0027 · Cited by 653
Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.003 · Cited by 648
Sterner, R. M., Sakemura, R., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881722 · Cited by 621
Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 607
Self-citationCombination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Maus, M. V., Haas, A. R., Beatty, G. L., Albelda, S. M., Levine, B. L., Liu, X., Zhao, Y., Kalos, M., & June, C. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0006 · Cited by 586
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Guedan, S., Posey, A. D., Shaw, C., Wing, A., Da, T., Patel, P. R., McGettigan, S. E., Casado-Medrano, V., Kawalekar, O. U., Uribe-Herranz, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96976 · Cited by 580
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Choi, B. D., Yu, X., Castano, A. P., Bouffard, A. A., Schmidts, A., Larson, R. C., Bailey, S. R., Boroughs, A. C., Frigault, M. J., Leick, M. B., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0192-1 · Cited by 571
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Ruella, M., Barrett, D. M., Kenderian, S. S., Shestova, O., Hofmann, T. J., Perazzelli, J., Klichinsky, M., Aikawa, V., Nazimuddin, F., Kozlowski, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87366 · Cited by 558
T cell stemness and dysfunction in tumors are triggered by a common mechanism
Vodnala, S. K., Eil, R., Kishton, R. J., Sukumar, M., Yamamoto, T. N., Ha, N.-H., Lee, P.-H., Shin, M., Patel, S. J., Yu, Z., et al. (2019) · Science · doi:10.1126/science.aau0135 · Cited by 552
Moon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5907 · Cited by 531
Torikai, H., Reik, A., Liu, P.-Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J. C., Kebriaei, P., Rabinovitch, B., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405365 · Cited by 528
Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 523
Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 506
Reactive Oxygen Species in the Tumor Microenvironment: An Overview
Weinberg, F., Ramnath, N., & Nagrath, D. (2019) · Cancers · doi:10.3390/cancers11081191 · Cited by 502
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Fu, W., Lei, C., Liu, S., Cui, Y., Wang, C., Qian, K., Li, T., Shen, Y., Fan, X., Lin, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12321-3 · Cited by 496
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
Tran, E., Chinnasamy, D., Yu, Z., Morgan, R. A., Lee, C.-C. R., Restifo, N. P., & Rosenberg, S. A. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130110 · Cited by 463
Hurton, L. V., Singh, H., Najjar, A. M., Switzer, K. C., Mi, T., Maiti, S., Olivares, S., Rabinovich, B., Huls, H., Forget, M.-A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610544113 · Cited by 461
Fitzgerald, J. C., Weiss, S. L., Maude, S. L., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., Shaw, P., Berg, R. A., June, C. H., Porter, D. L., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002053 · Cited by 459
Alizadeh, D., Wong, R. A., Yang, X., Wang, D., Pecoraro, J. R., Kuo, C.-F., Aguilar, B., Qi, Y., Ann, D. K., Starr, R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0466 · Cited by 453
Tchou, J., Zhao, Y., Levine, B. L., Zhang, P. J., Davis, M. M., Melenhorst, J. J., Kulikovskaya, I., Brennan, A. L., Liu, X., Lacey, S. F., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0189 · Cited by 452
Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
Wei, J., Long, L., Zheng, W., Dhungana, Y., Lim, S. A., Guy, C., Wang, Y., Wang, Y.-D., Qian, C., Xu, B., et al. (2019) · Nature · doi:10.1038/s41586-019-1821-z · Cited by 447
Chu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Programming CAR-T cells to kill cancer
Labanieh, L., Majzner, R. G., & Mackall, C. L. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0235-9 · Cited by 431
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., & Kurosawa, Y. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90502-x · Cited by 429
Chmielewski, M., & Abken, H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.063 · Cited by 429
Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03279 · Cited by 421
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D., & Brentjens, R. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10940-8 · Cited by 409
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
Rodgers, D. T., Mazagova, M., Hampton, E. N., Cao, Y., Ramadoss, N. S., Hardy, I. R., Schulman, A., Du, J., Wang, F., Singer, O., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524155113 · Cited by 397
A versatile system for rapid multiplex genome-edited CAR T cell generation
Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15218 · Cited by 397
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Liu, X., Zhang, Y., Cheng, C., Cheng, A. W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., & Wang, H. (2017) · Cell Research · doi:10.1038/cr.2016.142 · Cited by 396
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Jin, L., Tao, H., Karachi, A., Long, Y., Hou, A. Y., Na, M., Dyson, K. A., Grippin, A. J., Deleyrolle, L. P., Zhang, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11869-4 · Cited by 385
Chmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
Avanzi, M. P., Yeku, O., Li, X., Wijewarnasuriya, D. P., van Leeuwen, D. G., Cheung, K., Park, H., Purdon, T. J., Daniyan, A. F., Spitzer, M. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.051 · Cited by 341
Suarez, E. R., Chang, D.-K., Sun, J., Sui, J., Freeman, G. J., Signoretti, S., Zhu, Q., & Marasco, W. A. (2016) · Oncotarget · doi:10.18632/oncotarget.9114 · Cited by 340
Srivastava, S., Salter, A. I., Liggitt, D., Yechan-Gunja, S., Sarvothama, M., Cooper, K., Smythe, K. S., Dudakov, J. A., Pierce, R. H., Rader, C., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.003 · Cited by 334
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
Kotch, C., Barrett, D., & Teachey, D. T. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1629904 · Cited by 324
Urbanska, K., Lanitis, E., Poussin, M., Lynn, R. C., Gavin, B. P., Kelderman, S., Yu, J., Scholler, N., & Powell, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3890 · Cited by 322
Krenciute, G., Prinzing, B. L., Yi, Z., Wu, M.-F., Liu, H., Dotti, G., Balyasnikova, I. V., & Gottschalk, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0376 · Cited by 319
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
Torikai, H., Reik, A., Soldner, F., Warren, E. H., Yuen, C., Zhou, Y., Crossland, D. L., Huls, H., Littman, N., Zhang, Z., et al. (2013) · Blood · doi:10.1182/blood-2013-03-478255 · Cited by 311
Li, S., Siriwon, N., Zhang, X., Yang, S., Jin, T., He, F., Kim, Y. J., Mac, J., Lu, Z., Wang, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0867 · Cited by 300
Stephan, M. T., Ponomarev, V., Brentjens, R. J., Chang, A. H., Dobrenkov, K. V., Heller, G., & Sadelain, M. (2007) · Nature Medicine · doi:10.1038/nm1676 · Cited by 299
O'Leary, M. C., Lu, X., Huang, Y., Lin, X., Mahmood, I., Przepiorka, D., Gavin, D., Lee, S., Liu, K., George, B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2035 · Cited by 298
Shum, T., Omer, B., Tashiro, H., Kruse, R. L., Wagner, D. L., Parikh, K., Yi, Z., Sauer, T., Liu, D., Parihar, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0538 · Cited by 297
Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
MacLeod, D. T., Antony, J., Martin, A. J., Moser, R. J., Hekele, A., Wetzel, K. J., Brown, A. E., Triggiano, M. A., Hux, J. A., Pham, C. D., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.005 · Cited by 276
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Qin, H., Ramakrishna, S., Nguyen, S., Fountaine, T. J., Ponduri, A., Stetler-Stevenson, M., Yuan, C. M., Haso, W., Shern, J. F., Shah, N. N., et al. (2018) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2018.10.006 · Cited by 273
Batra, S. A., Rathi, P., Guo, L., Courtney, A. N., Fleurence, J., Balzeau, J., Shaik, R. S., Nguyen, T. P., Wu, M.-F., Bulsara, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0293 · Cited by 268
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Chang, Z. L., Lorenzini, M. H., Chen, X., Tran, U., Bangayan, N. J., & Chen, Y. Y. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2565 · Cited by 259
Self-citationLoss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
Boice, M., Salloum, D., Mourcin, F., Sanghvi, V., Amin, R., Oricchio, E., Jiang, M., Mottok, A., Denis-Lagache, N., Ciriello, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.032 · Cited by 257
Parihar, R., Rivas, C., Huynh, M., Omer, B., Lapteva, N., Metelitsa, L. S., Gottschalk, S. M., & Rooney, C. M. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0572 · Cited by 254
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
Cartellieri, M., Feldmann, A., Koristka, S., Arndt, C., Loff, S., Ehninger, A., von Bonin, M., Bejestani, E. P., Ehninger, G., & Bachmann, M. P. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.61 · Cited by 247
Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells
Montel-Hagen, A., Seet, C. S., Li, S., Chick, B., Zhu, Y., Chang, P., Tsai, S., Sun, V., Lopez, S., Chen, H.-C., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.12.011 · Cited by 243
Kuhn, N. F., Purdon, T. J., van Leeuwen, D. G., Lopez, A. V., Curran, K. J., Daniyan, A. F., & Brentjens, R. J. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.006 · Cited by 243
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
Zhang, Y., Zhang, X., Cheng, C., Mu, W., Liu, X., Li, N., Wei, X., Liu, X., Xia, C., & Wang, H. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0543-6 · Cited by 239
Pharmacologic control of CAR-T cell function using dasatinib
Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028720 · Cited by 239
Markley, J. C., & Sadelain, M. (2010) · Blood · doi:10.1182/blood-2009-09-241398 · Cited by 228
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Bouchkouj, N., Kasamon, Y. L., de Claro, R. A., George, B., Lin, X., Lee, S., Blumenthal, G. M., Bryan, W., McKee, A. E., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2743 · Cited by 226
An oxygen sensitive self-decision making engineered CAR T-cell
Juillerat, A., Marechal, A., Filhol, J. M., Valogne, Y., Valton, J., Duclert, A., Duchateau, P., & Poirot, L. (2017) · Scientific Reports · doi:10.1038/srep39833 · Cited by 225
Zah, E., Nam, E., Bhuvan, V., Tran, U., Ji, B. Y., Gosliner, S. B., Wang, X., Brown, C. E., & Chen, Y. Y. (2020) · Nature Communications · doi:10.1038/s41467-020-16160-5 · Cited by 222
Self-citationCRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells
Jung, I.-Y., Kim, Y.-Y., Yu, H.-S., Lee, M., Kim, S., & Lee, J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0030 · Cited by 222
Lai, J., Mardiana, S., House, I. G., Sek, K., Henderson, M. A., Giuffrida, L., Chen, A. X. Y., Todd, K. L., Petley, E. V., Chan, J. D., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0676-7 · Cited by 219
Ligtenberg, M. A., Mougiakakos, D., Mukhopadhyay, M., Witt, K., Lladser, A., Chmielewski, M., Riet, T., Abken, H., & Kiessling, R. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1401710 · Cited by 218
Curran, K. J., Seinstra, B. A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D. G., Purdon, T., Pegram, H. J., & Brentjens, R. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.4 · Cited by 217
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Stancovski, I., Schindler, D. G., Waks, T., Yarden, Y., Sela, M., & Eshhar, Z. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.11.6577 · Cited by 216
Paleolithic to Bronze Age Siberians Reveal Connections with First Americans and across Eurasia
Yu, H., Spyrou, M. A., Karapetian, M., Shnaider, S., Radzevičiūtė, R., Nägele, K., Neumann, G. U., Penske, S., Zech, J., Lucas, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.037 · Cited by 216
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Moritz, D., Wels, W., Mattern, J., & Groner, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4318 · Cited by 208
Hombach, A. A., Heiders, J., Foppe, M., Chmielewski, M., & Abken, H. (2012) · OncoImmunology · doi:10.4161/onci.19855 · Cited by 200
Haynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., & Darcy, P. K. (2002) · Blood · doi:10.1182/blood-2002-04-1041 · Cited by 197
Newick, K., O'Brien, S., Sun, J., Kapoor, V., Maceyko, S., Lo, A., Puré, E., Moon, E., & Albelda, S. M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0263 · Cited by 197
Xu, X., Huang, W., Heczey, A., Liu, D., Guo, L., Wood, M., Jin, J., Courtney, A. N., Liu, B., Di Pierro, E. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0421 · Cited by 192
Self-citationEliopoulos, A. G., Davies, C., Knox, P. G., Gallagher, N. J., Afford, S. C., Adams, D. H., & Young, L. S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5503-5515.2000 · Cited by 190
Wilkie, S., Burbridge, S. E., Chiapero-Stanke, L., Pereira, A. C. P., Cleary, S., van der Stegen, S. J. C., Spicer, J. F., Davies, D. M., & Maher, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127951 · Cited by 189
Role of the immunosuppressive microenvironment in immunotherapy
Tormoen, G. W., Crittenden, M. R., & Gough, M. J. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.018 · Cited by 189
Genßler, S., Burger, M. C., Zhang, C., Oelsner, S., Mildenberger, I., Wagner, M., Steinbach, J. P., & Wels, W. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1119354 · Cited by 187
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Leen, A. M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D., Heslop, H. E., Rooney, C. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.47 · Cited by 184
The Loss of TET2 Promotes CD8+ T Cell Memory Differentiation
Carty, S. A., Gohil, M., Banks, L. B., Cotton, R. M., Johnson, M. E., Stelekati, E., Wells, A. D., Wherry, E. J., Koretzky, G. A., & Jordan, M. S. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700559 · Cited by 172
Shalabi, H., Kraft, I. L., Wang, H.-W., Yuan, C. M., Yates, B., Delbrook, C., Zimbelman, J. D., Giller, R., Stetler-Stevenson, M., Jaffe, E. S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183459 · Cited by 170
Siska, P. J., van der Windt, G. J. W., Kishton, R. J., Cohen, S., Eisner, W., MacIver, N. J., Kater, A. P., Weinberg, J. B., & Rathmell, J. C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502464 · Cited by 163
Sakemura, R., Terakura, S., Watanabe, K., Julamanee, J., Takagi, E., Miyao, K., Koyama, D., Goto, T., Hanajiri, R., Nishida, T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0043 · Cited by 161
Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
Raj, D., Yang, M.-H., Rodgers, D. T., Hampton, E. N., Begum, J., Mustafa, A., Lorizio, D., Garces, I., PROPPER, D. J., Kench, J. G., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316595 · Cited by 160
Liu, Y., Di, S., Shi, B., Zhang, H., Wang, Y., Wu, X., Luo, H., Wang, H., Li, Z., & Jiang, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800033 · Cited by 150
Enhancement of T cell recruitment and infiltration into tumours
Oelkrug, C., & Ramage, J. M. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12382 · Cited by 146
Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects
Georgiadis, C., Preece, R., Nickolay, L. E., Etuk, A., Petrova, A., Ładoń, D., Danyi, A., Humphryes-Kirilov, N., Ajetunmobi, A., Kim, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.025 · Cited by 141
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Griffioen, M., van Egmond, E. H. M., Kester, M. G. D., Willemze, R., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2009) · Haematologica · doi:10.3324/haematol.2008.001677 · Cited by 140
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
Chen, N., Morello, A., Tano, Z. E., & Adusumilli, P. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1273302 · Cited by 134
Lee, Y. G., Marks, I. S., Srinivasarao, M., Kanduluru, A. K., Mahalingam, S. M., Liu, X., Chu, H., & Low, P. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1834 · Cited by 131
The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells
Bachmann, M. P. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.05.003 · Cited by 131
Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
Riese, M. J., Wang, L. S., Moon, E. K., Joshi, R. P., Ranganathan, A., June, C. H., Koretzky, G. A., & Albelda, S. Μ. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3874 · Cited by 129
Marin, V., Cribioli, E., Philip, B., Tettamanti, S., Pizzitola, I., Biondi, A., Biagi, E., & Pulè, M. A. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.050 · Cited by 127
Modulation of chimeric antigen receptor surface expression by a small molecule switch
Juillerat, A., Tkach, D., Busser, B. W., Temburni, S., Valton, J., Duclert, A., Poirot, L., Depil, S., & Duchateau, P. N. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0537-3 · Cited by 125
Ede, C., Chen, X., Lin, M.-Y., & Chen, Y. Y. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00266 · Cited by 124
Self-citationMasked Chimeric Antigen Receptor for Tumor-Specific Activation
Han, X., Bryson, P. D., Zhao, Y., Cinay, G. E., Li, S., Guo, Y., Siriwon, N., & Wang, P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.011 · Cited by 117
A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
Valton, J., Guyot, V., Maréchal, A., Filhol, J.-M., Juillerat, A., Duclert, A., Duchateau, P. N., & Poirot, L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.104 · Cited by 114
Serafini, M., Manganini, M., Borleri, G., Bonamino, M., Imberti, L., Biondi, A., Golay, J., Rambaldi, A., & Introna, M. (2004) · Human Gene Therapy · doi:10.1089/10430340460732463 · Cited by 110
Ohno, M., Ohkuri, T., Kosaka, A., Tanahashi, K., June, C. H., Natsume, A., & Okada, H. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-21 · Cited by 108
TGF‐β–responsive CAR‐T cells promote anti‐tumor immune function
Hou, A. J., Chang, Z. L., Lorenzini, M. H., Zah, E., & Chen, Y. Y. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10097 · Cited by 106
Self-citationMamonkin, M., Mukherjee, M., Srinivasan, M., Sharma, S., Gomes‐Silva, D., Mo, F., Krenciute, G., Orange, J. S., & Brenner, M. K. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0126 · Cited by 106
Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform
Herzig, E., Chan, K., Packard, T. A., Vardi, N., Schwarzer, R., Gramatica, A., Deeks, S. G., Williams, S. R., Landgraf, K. E., Killeen, N. P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.002 · Cited by 106
Lee, Y. G., Chu, H., Lu, Y. J., Leamon, C. P., Srinivasarao, M., Putt, K. S., & Low, P. S. (2019) · Nature Communications · doi:10.1038/s41467-019-10565-7 · Cited by 105
Quintarelli, C., Sivori, S., Caruso, S., Carlomagno, S., Falco, M., Boffa, I., Orlando, D., Guercio, M., Abbaszadeh, Z., Sinibaldi, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0613-7 · Cited by 98
Collinson-Pautz, M. R., Chang, W.-C., Lu, A., Khalil, M., Crisostomo, J., Lin, P.-Y., Mahendravada, A., Shinners, N. P., Brandt, M. E., Zhang, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0417-9 · Cited by 94
Casucci, M., Falcone, L., Camisa, B., Norelli, M., Porcellini, S., Stornaiuolo, A., Ciceri, F., Traversari, C., Bordignon, C., Bonini, C., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00507 · Cited by 89
Shin, J. H., Park, H. B., Oh, Y. M., Lim, D. P., Lee, J. E., Seo, H. H., Lee, S. J., Eom, H., Kim, I.-H., Lee, S. H., et al. (2012) · Blood · doi:10.1182/blood-2011-09-380519 · Cited by 86
Engineering CAR-T Cells for Improved Function Against Solid Tumors
Morgan, M. A., & Schambach, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02493 · Cited by 82
A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
Hoogi, S., Eisenberg, V., Mayer, S., Shamul, A., Barliya, T., & Cohen, C. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0721-y · Cited by 82
Menger, L., Śledzińska, A., Bergerhoff, K. F., Vargas, F. A., Smith, J. N. P., Poirot, L., Pulè, M. A., Herrero, J., Peggs, K. S., & Quezada, S. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3352 · Cited by 80
miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy
Sasaki, K., Kohanbash, G., Hoji, A., Ueda, R., McDonald, H. A., Reinhart, T., Martinson, J., Lotze, M., Marincola, F., Wang, E., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-17 · Cited by 75
Wiesinger, M., März, J., Kummer, M., Schuler, G., Dörrie, J., Schuler‐Thurner, B., & Schaft, N. (2019) · Cancers · doi:10.3390/cancers11081198 · Cited by 73
Reighard, S. D., Cranert, S. A., Rangel, K., Ali, A., Gyurova, I. E., de la Cruz-Lynch, A. T., Tuazon, J. A., Khodoun, M. V., Kottyan, L. C., Smith, D. F., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100003 · Cited by 57
Human CD8 T cells generated in vitro from hematopoietic stem cells are functionally mature
Awong, G., Herer, E., Motte-Mohs, R. N. L., & Zúñiga‐Pflücker, J. C. (2011) · BMC Immunology · doi:10.1186/1471-2172-12-22 · Cited by 49
Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation
Lo, A. S., Taylor, J. R., Farzaneh, F., Kemeny, D. M., Dibb, N. J., & Maher, J. F. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.09.010 · Cited by 45
Chimeric antigen receptor–T cells with cytokine neutralizing capacity
Tan, A. H. J., Vinanica, N., & Campana, D. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001287 · Cited by 45
Chemically Programmable and Switchable CAR‐T Therapy
Qi, J., Tsuji, K., Hymel, D., Burke, T. R., Hudecek, M., Rader, C. M., & Peng, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005432 · Cited by 45
Weber, E. W., Lynn, R. C., Parker, K. R., Anbunathan, H., Lattin, J., Sotillo, E., Good, Z., Malipatlolla, M., Xu, P., Vandris, P., et al. (2020) · doi:10.1101/2020.01.26.920496 · Cited by 18
Efficient Gene Editing in Primary Human T Cells
Chen, Y. Y. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.001 · Cited by 18
Self-citation
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
A guide to antigen processing and presentation
Pishesha, N., Harmand, T. J., & Ploegh, H. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00707-2 · Cited by 805
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., Zhang, M., Peng, Z., Zhou, J., Cao, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01800-8 · Cited by 604
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
“CAR T cell therapy has demonstrated remarkable success by utilizing engineered T cells with tumor antigens that lead to the recognition and attack of tumor cells in blood cancers; however, this method still remains a big challenge for treating solid tumors partially due to TGFβ-mediated immunosuppression.(301) Inhibit…”
BackgroundOvercoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Metadata
- Authors
- Hong, M., Clubb, J. D., & Chen, Y. Y.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 38
- Issue
- 4
- Pages
- 473-488
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3046624515
- Cited by
- 639
- References
- 185
- FWCI
- 25.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.